CG
PYXS icon

Cutler Group’s Pyxis Oncology PYXS Stock Holding History

Cutler Group’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-51
Closed – – 4192
2023
Q3 		$0 Buy
+51
New +$118 ﹤0.01% 4230

Other funds holding PYXS

LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cutler Group's PYXS Position: Q4 2023 in Review

Cutler Group sold out of Pyxis Oncology (PYXS) in Q4 2023, closing a stake of 51 shares.

Cutler Group first reported a position in PYXS in Q3 2023 and held it in 1 quarter. The position peaked at $0 in Q3 2023. 51 funds tracked by Wall St. Rank hold PYXS as of Q4 2023.

  • Cutler Group reported no remaining Pyxis Oncology position as of Q4 2023 after selling out during the quarter.
  • Cutler Group sold 51 Pyxis Oncology shares in Q4 2023.
  • Cutler Group first reported a position in Pyxis Oncology in Q3 2023 and held it in 1 quarter.
  • Cutler Group's Pyxis Oncology position peaked at $0 in Q3 2023.
  • 51 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.